Federal Register / Vol. 76, No. 60 / Tuesday, March 29, 2011 / Notices 17421 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Form Number of 

respondents 

Number of 

responses per 

respondent 

Average burden 

per response 

(in hours) 

Total burden 

hours 

Prison official in DOC ........... NSPH Questionnaire ............ 17 1 4 68 

Total ............................... ............................................... .............................. .............................. .............................. 68 

Daniel Holcomb, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2011–7300 Filed 3–28–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number NIOSH–227] 

Request for Information on Conditions 

Relating to Cancer To Consider for the 

World Trade Center Health Program 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice and extension of public 

comment period. 

SUMMARY: On March 8, 2011, the 

Director of the National Institute of 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) published 

a notice in the Federal Register (76 FR 

12740) requesting information from the 

public on three questions regarding 

conditions relating to cancer for 

consideration under the World Trade 

Center Health Program. Written 

comment was to be received by March 

31, 2011. NIOSH has received comment 

about extending the request for 

information to include persons living 

and working in the affected area. In 

consideration of that comment, the 

Director of NIOSH is modifying one of 

the questions posed in the Federal 

Register and extending the public 

comment period to April 29, 2011. 

DATES: Written or electronic comments 

must be received on or before April 29, 

2011. Please refer to SUPPLEMENTARY

INFORMATION for additional information. 

ADDRESSES: You may submit comments, 

identified by docket number NIOSH– 

227, by any of the following methods: 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C34, 4676 

Columbia Parkway, Cincinnati, OH 

45226. 

• Facsimile: (513) 533–8285. 

• E-mail: nioshdocket@cdc.gov. 

All information received in response to 

this notice will be available for public 

examination and copying at the NIOSH 

Docket Office, 4676 Columbia Parkway, 

Cincinnati, Ohio 45226. The comment 

period for NIOSH–227 will close on 

April 29, 2011. All comments received 

will be available on the NIOSH Docket 

Web page at http://www.cdc.gov/niosh/ 

docket, and comments will be available 

in writing by request. NIOSH includes 

all comments received without change 

in the docket and the electronic docket, 

including any personal information 

provided. 

FOR FURTHER INFORMATION CONTACT: Dori 

Reissman, M.D., NIOSH, Patriots Plaza 

Suite 9200, 395 E. St., SW., Washington, 

DC 20201, telephone (202) 245–0625 or 

e-mail nioshdocket@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

Director of the National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) serves as 

the World Trade Center (WTC) Program 

Administrator for certain functions 

related to the WTC Health Program 

established by the James Zadroga 9/11 

Health and Compensation Act (Pub. L. 

111–347). In accordance with Section 

3312(a)(5)(A) of that Act, the WTC 

Program Administrator is conducting a 

review of all available scientific and 

medical evidence to determine if, based 

on the scientific evidence, cancer or a 

certain type of cancer should be added 

to the applicable list of health 

conditions covered by the World Trade 

Center Health Program. 

The WTC Program Administrator is 

requesting information on the following: 

(1) Relevant reports, publications, and 

case information of scientific and 

medical findings where exposure to 

airborne toxins, any other hazard, or any 

other adverse condition resulting from 

the September 11, 2001 terrorist attacks, 

is substantially likely to be a significant 

factor in aggravating, contributing to, or 

causing cancer or a type of cancer; (2) 

clinical findings from the Clinical 

Centers of Excellence providing 

monitoring and treatment services to 

WTC responders (i.e., those persons 

who performed rescue, recovery, cleanup and remediation work on the WTC 

disaster sites) and community members 

directly exposed to the dust cloud, gases 

and vapors on 9/11/01 and those living 

and working in the affected area; and (3) 

input on the scientific criteria to be used 

by experts to evaluate the weight of the 

medical and scientific evidence 

regarding such potential health 

conditions. 

Dated: March 22, 2011. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2011–7299 Filed 3–28–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

[OMB No. 0980–0162] 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects/Title: State 

Developmental Disabilities Council 5- 

Year State Plan. 

Description 

A Plan developed by the State 

Council on Developmental Disabilities 

is required by Federal statute. Each 

State Council on Developmental 

Disabilities must develop the plan, 

provide for public comments in the 

State, provide for approval by the State’s 

Governor, and finally submit the plan 

on a five-year basis. On an annual basis, 

the Council must review the plan and 

make any amendments. The State Plan 

will be used (1) by the Council as a 

planning document; (2) by the citizenry 

of the State as a mechanism for 

commenting on the plans of the 

Council; and (3) by the Department as 

a stewardship tool, for ensuring 

compliance with the Developmental 

Disabilities Assistance and Bill of Rights 

Act, as one basis for providing technical 

assistance (e.g., during site visits), and 


jlentini on DSKJ8SOYB1PROD with NOTICES
17422 Federal Register / Vol. 76, No. 60 / Tuesday, March 29, 2011 / Notices 

as a support for management decision 

making. 

Respondents: 55 State Developmental 

Disabilities Councils. 

ANNUAL BURDEN ESTIMATES

Instrument Number of respondents 

Number of responses per respondent Average burden 

hours per response 

Total burden 

hours 

Plan .................................................................................................. 55 1 367 20,185 

Estimated Total Annual Burden 

Hours: 

In compliance with the requirements 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2011–7157 Filed 3–28–11; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0002] 

Orthopaedic and Rehabilitation 

Devices Panel of the Medical Devices 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Orthopaedic and 

Rehabilitation Devices Panel of the 

Medical Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on May 12, 2011, from 8 a.m. to 6 

p.m. 

Location: Hilton, Washington DC 

North/Gaithersburg, Salons A, B, C, and 

D, 620 Perry Pkwy., Gaithersburg, MD 

20877. 

Contact Person: Margaret McCabeJanicki, Food and Drug Administration, 

Center for Devices and Radiological 

Health, 10903 New Hampshire Ave., 

Bldg. 66, rm. 1535, Silver Spring, MD 

20993–0002, 301–796–7029, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), and follow the 

prompts to the desired center or product 

area. Please call the Information Line for 

up-to-date information on this meeting. 

A notice in the Federal Register about 

last minute modifications that impact a 

previously announced advisory 

committee meeting cannot always be 

published quickly enough to provide 

timely notice. Therefore, you should 

always check the Agency’s Web site and 

call the appropriate advisory committee 

hot line/phone line to learn about 

possible modifications before coming to 

the meeting. 

Agenda: On May 12, 2011, the 

committee will discuss, make 

recommendations, and vote on 

information related to the premarket 

approval application (PMA) for the 

Augment Bone Graft, sponsored by 

Biomimetic Therapeutics, Inc. The 

intended use of the device is as an 

alternative bone grafting substitute to 

autologous bone graft in applications to 

facilitate fusion in the ankle and foot 

without necessitating an additional 

invasive procedure to harvest the graft. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before May 5, 2011. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Those individuals 

interested in making formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before April 25, 

2011. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by April 28, 2011. 

Persons attending FDA’s advisory 

committee meetings are advised that the 


jlentini on DSKJ8SOYB1PROD with NOTICES